VEGFA and pulmonary arterial hypertension: Of relevance to this point, bone marrow-derived mononuclear cells, administered 4 weeks after monocrotaline administration, improved pulmonary hypertension through both increased VEGF expression [55] and inhibition of soluble inflammatory mediators [56].